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Abstract 
Objective: To investigate whether alteration in the composition of the gut 
microbiota, in terms of species richness, distribution and functional potential, 
could be associated with immune system alteration in Clinically Isolated 
Syndrome (CIS), as it offers the opportunity to study disease processes in the 
supposed earliest stage of Multiple Sclerosis (MS). 
Background: Which are the triggers that convert self-reactive lymphocytes, 
normal components of the immune repertoire, into an autoaggressive phenotype 
facilitating the first episode of demyelization in MS are still poorly understood. 
Alterations in the composition of the gut microbiota are now suggested as having a 
role in the etiology, course and treatment of MS through gut-brain 
communications that likely involve the immune system. 
Design/Methods: Stool and blood samples were collected from CIS patients and 
Healthy Volunteers (HV). DNA isolated from stools were subjected to shotgun 
metagenomic sequencing strategy in order to discover the microbiota composition 
as well as the microbial function. T helper (Th)17 and T regulatory (Treg) cells 
were analyzed by FACS in the peripheral blood (PB). 
Results: A clear separation of the microbiota composition of CIS patients 
compared to HV was observed by using Principal Component Analysis. Two of 
the identified taxa droving cluster separation and decreased in CIS microbiota 
belong to butyrate-producing bacteria. In the PB, CIS patients displayed an 
increase of phatogenic Th17 cells expressing Toll Like Receptor 2 and a decrease 
of Treg cells producing Interleukin-10 and expressing CD39 compared to HV, 
evidences that could be indicative of gut microbial modulation. 
Conclusions: These findings indicate that gut microbial dysbiosis exist at the 
onset of MS and could be suggestive of the pro-inflammatory milieu observed in 
the periphery. The analysis on metagenomic content and microbial gene 
identification will allow us to design strategies to modulate the immune system 
through alteration of gut microbiome. 
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